You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Validation of a salivary miRNA diagnostic test for autism spectrum disorder

    SBC: Quadrant Biosciences Inc.            Topic: 105

    Project Summary Abstract Autism spectrum disorder ASD is a continuum of neurodevelopmental characteristics that includes deficits in communication and social interaction as well as restrictive repetitive interests and behaviors ASD is an increasing public health concern with about in American children diagnosed with ASD in a fold increase in prevalence over the past years T ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Therapy for drug resistant influenza strains by nucleic acid targeting of respiratory airways

    SBC: Abcombi Biosciences Inc            Topic: NIAID

    PROJECT SUMMARY Antiviral drugs are a crucial countermeasure for influenza A virus IAV particularly in circumstances of increased IAV incidence or if a vaccine is unavailable e g virulent H N IAV However the emergence of IAV strains that are resistant to current antivirals H N underscores the need for new treatment strategies particularly those that modify the host response IAVs ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. The Effects of an Oral Nitric Oxide Lozenge on Peripheral Artery Disease

    SBC: Neogenis Laboratories, Inc.            Topic: 213

    Abstract Peripheral artery disease PAD is a common circulatory problem in which narrowed arteries reduce blood flow to your limbs thereby restricting blood flow During exercise or simply walking there is not sufficient blood flow to keep up with the metabolic demand This causes symptoms most notably leg pain when walking intermittent claudication PAD is also likely to be a sign of more w ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Target Identification for Novel Small Molecule Therapeutic for Alzheimer's disease

    SBC: CoPlex Therapeutics, LLC            Topic: NIA

    ABSTRACT Traditional approaches to drug development for Alzheimer s disease are becoming increasingly expensive and in many cases disappointingly unsuccessful Based on preliminary in vitro and in vivo studies we have identified a novel small molecule methyl dimethyl oxo dihydrobenzo c naphthyridine carboxylate UK that significantly decreases A production and pro in ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Targeted Epigenetic Therapy for Triple-Negative Breast Cancer

    SBC: PARKSIDE SCIENTIFIC INC.            Topic: 102

    DESCRIPTIONprovided by applicantTriple negative breast cancerTNBCis one of the most aggressive forms of human cancerand currently has no targeted therapyChemotherapy is the only available treatment for TNBC patientsbut is deleterious and not effective once tumor spreadsTNBC represents a major unmet medical needaboutof breast cancer incidenceswomen worldwide inare TNBCTNBC disproportionally affects ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. STAT Inhibitors for Asthma Therapy

    SBC: Atrapos Therapeutics, LLC            Topic: NIAID

    Asthma a chronic disease of the lungs that affects adults and children of all ages has markedly increased in incidence prevalence and severity over the past several decades with a prevalence of in the U S The current standard of care for asthma consists of the combination of long acting beta adrenergic receptor agonists which relieve airway constriction and glucocorticosteroids which ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Smaller, Brighter Probes for Correlative Super-resolution and Electron Microscopy

    SBC: NANOPROBES INC            Topic: NIGMS

    DESCRIPTION provided by applicant We propose new probes for correlative super resolution fluorescence and electron microscopy that use biorthogonal reactions Click SNAP and HALO tags to label targets in living cells To minimize quenching of the fluorophores by the gold particles the small Undecagold gold atoms gold cluster label will be used this has minimal absorption at wavelengt ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Preclinical Evaluation of NCS-382 in Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD)

    SBC: SPERAGEN, INC.            Topic: 107

    SUMMARY Succinic semialdehyde dehydrogenase deficiency SSHDHD is an autosomal recessively inherited ultra rare disorder caused by accumulation of two neuromodulators in tissues and biofluids hydroxybutyrate GHB and aminobutyric acid GABA It is believed that the toxic action of GABA and GHB is mediated by their action on specific receptors widely distributed in the brain and other organ ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Oral Small Molecule STAT3 Inhibitor to Treat Cachexia in Chronic Kidney Disease

    SBC: StemMed, Ltd.            Topic: NIDDK

    DESCRIPTION provided by applicant Chronic kidney disease CKD is a major public health problem in the US with an estimated prevalence of million patients enter hemodialysis or peritoneal dialysis programs yearly A serious complication in of patients with CKD is cachexia or muscle wasting which decreases quality of life and increases morbidity and mortality Unfortunately ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Optimization of the Production and Isolation of the Novel Antifungal Occidiofungin

    SBC: Sano Chemicals, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Occidiofungin is a cyclic nonribosomally synthesized antifungal peptide with submicromolar fungicidal activity against a broad spectrum of fungi Occidiofungin is produced by the Gram negative bacterium Burkholderia contaminans From our structural characterization studies occidiofungin was determined to have a unique chemical composition Our studies have als ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government